Health Care [ 4/12 ] | Biotechnology [ 20/73 ]
NASDAQ | Common Stock
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma.
In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor.
In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services.
The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions.
Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | -1.73 | - |
| Apr 16, 25 | -1.82 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 233.70 M Decreased by -71.63% | -590.77 M Decreased by -462.43% | Decreased by -252.79% Decreased by -1.38 K% |
| Mar 31, 25 | 156.90 M Decreased by -61.90% | -568.43 M Decreased by -797.46% | Decreased by -362.28% Decreased by -1.93 K% |
| Dec 31, 24 | 156.90 M Increased by +97.90% | -568.43 M Decreased by -8.63% | Decreased by -362.28% Increased by +45.11% |
| Sep 30, 24 | 78.45 M Increased by +97.90% | -284.22 M Decreased by -8.63% | Decreased by -362.28% Increased by +45.11% |
| Jun 30, 24 | 823.75 M Increased by +477.26% | 163.00 M Increased by +140.51% | Increased by +19.79% Increased by +107.02% |
| Mar 31, 24 | 411.87 M Increased by +292.80% | 81.50 M Increased by +118.46% | Increased by +19.79% Increased by +104.70% |
| Dec 31, 23 | 79.28 M Decreased by -24.39% | -523.29 M Decreased by -18.53% | Decreased by -660.01% Decreased by -56.77% |
| Sep 30, 23 | 39.64 M Increased by +1.73 K% | -261.64 M Increased by +33.12% | Decreased by -660.01% Increased by +96.35% |